The European Medicines Agency (EMA) has accepted for review Eisai and Biogen’s marketing authorization application (MAA) submitted for lecanemab to treat early Alzheimer’s disease (AD).
Eisai has submitted a marketing authorization application to the Pharmaceuticals and Medical Devices Agency (PMDA) for investigational anti-amyloid beta (Aβ) protofibril antibody lecanemab for early Alzheimer’s Disease (AD) in Japan.
The US Food and Drug Administration (FDA) has accepted review of a new drug application (NDA) filed by Biohaven Pharmaceutical for zavegepant nasal spray.
GNS Healthcare and Arvinas have entered into a collaboration for generating insights to help expedite neurodegenerative disease drug development.
Shape Therapeutics has entered into a multi-target strategic collaboration and licence agreement with Roche to develop gene therapy for particular targets in the areas of Alzheimer’s disease, Parkinson’s disease, and rare diseases.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.